Cargando…

Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I

Bisindolylmaleimide I (BIM-I) is a competitive pan protein kinase C inhibitor with anti-inflammatory and anti-metastatic properties, suggested to treat inflammatory diseases and various cancer entities. However, despite its therapeutic potential, BIM-I has two major drawbacks, i.e., it has a poor wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Shkodra, Blerina, Press, Adrian T., Vollrath, Antje, Nischang, Ivo, Schubert, Stephanie, Hoeppener, Stephanie, Haas, Dorothee, Enzensperger, Christoph, Lehmann, Marc, Babic, Petra, Benecke, Kay Jovana, Traeger, Anja, Bauer, Michael, Schubert, Ulrich S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698893/
https://www.ncbi.nlm.nih.gov/pubmed/33218172
http://dx.doi.org/10.3390/pharmaceutics12111110
_version_ 1783615930025115648
author Shkodra, Blerina
Press, Adrian T.
Vollrath, Antje
Nischang, Ivo
Schubert, Stephanie
Hoeppener, Stephanie
Haas, Dorothee
Enzensperger, Christoph
Lehmann, Marc
Babic, Petra
Benecke, Kay Jovana
Traeger, Anja
Bauer, Michael
Schubert, Ulrich S.
author_facet Shkodra, Blerina
Press, Adrian T.
Vollrath, Antje
Nischang, Ivo
Schubert, Stephanie
Hoeppener, Stephanie
Haas, Dorothee
Enzensperger, Christoph
Lehmann, Marc
Babic, Petra
Benecke, Kay Jovana
Traeger, Anja
Bauer, Michael
Schubert, Ulrich S.
author_sort Shkodra, Blerina
collection PubMed
description Bisindolylmaleimide I (BIM-I) is a competitive pan protein kinase C inhibitor with anti-inflammatory and anti-metastatic properties, suggested to treat inflammatory diseases and various cancer entities. However, despite its therapeutic potential, BIM-I has two major drawbacks, i.e., it has a poor water solubility, and it binds the human ether-à-go-go-related gene (hERG) ion channels, potentially causing deadly arrhythmias. In this case, a targeted delivery of BIM-I is imperative to minimize peripheral side effects. To circumvent these drawbacks BIM-I was encapsulated into nanoparticles prepared from poly(lactic-co-glycolic acid) (PLGA) functionalized by the near-infrared dye DY-635. DY-635 served as an active targeting moiety since it selectively binds the OATP1B1 and OATP1B3 transporters that are highly expressed in liver and cancer cells. PLGA-DY-635 (BIM-I) nanoparticles were produced by nanoprecipitation and characterized using dynamic light scattering, analytical ultracentrifugation, and cryogenic transmission electron microscopy. Particle sizes were found to be in the range of 20 to 70 nm, while a difference in sizes between the drug-loaded and unloaded particles was observed by all analytical techniques. In vitro studies demonstrated that PLGA-DY-635 (BIM-I) NPs prevent the PKC activation efficiently, proving the efficacy of the inhibitor after its encapsulation, and suggesting that BIM-I is released from the PLGA-NPs. Ultimately, our results present a feasible formulation strategy that improved the cytotoxicity profile of BIM-I and showed a high cellular uptake in the liver as demonstrated in vivo by intravital microscopy investigations.
format Online
Article
Text
id pubmed-7698893
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76988932020-11-29 Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I Shkodra, Blerina Press, Adrian T. Vollrath, Antje Nischang, Ivo Schubert, Stephanie Hoeppener, Stephanie Haas, Dorothee Enzensperger, Christoph Lehmann, Marc Babic, Petra Benecke, Kay Jovana Traeger, Anja Bauer, Michael Schubert, Ulrich S. Pharmaceutics Article Bisindolylmaleimide I (BIM-I) is a competitive pan protein kinase C inhibitor with anti-inflammatory and anti-metastatic properties, suggested to treat inflammatory diseases and various cancer entities. However, despite its therapeutic potential, BIM-I has two major drawbacks, i.e., it has a poor water solubility, and it binds the human ether-à-go-go-related gene (hERG) ion channels, potentially causing deadly arrhythmias. In this case, a targeted delivery of BIM-I is imperative to minimize peripheral side effects. To circumvent these drawbacks BIM-I was encapsulated into nanoparticles prepared from poly(lactic-co-glycolic acid) (PLGA) functionalized by the near-infrared dye DY-635. DY-635 served as an active targeting moiety since it selectively binds the OATP1B1 and OATP1B3 transporters that are highly expressed in liver and cancer cells. PLGA-DY-635 (BIM-I) nanoparticles were produced by nanoprecipitation and characterized using dynamic light scattering, analytical ultracentrifugation, and cryogenic transmission electron microscopy. Particle sizes were found to be in the range of 20 to 70 nm, while a difference in sizes between the drug-loaded and unloaded particles was observed by all analytical techniques. In vitro studies demonstrated that PLGA-DY-635 (BIM-I) NPs prevent the PKC activation efficiently, proving the efficacy of the inhibitor after its encapsulation, and suggesting that BIM-I is released from the PLGA-NPs. Ultimately, our results present a feasible formulation strategy that improved the cytotoxicity profile of BIM-I and showed a high cellular uptake in the liver as demonstrated in vivo by intravital microscopy investigations. MDPI 2020-11-18 /pmc/articles/PMC7698893/ /pubmed/33218172 http://dx.doi.org/10.3390/pharmaceutics12111110 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shkodra, Blerina
Press, Adrian T.
Vollrath, Antje
Nischang, Ivo
Schubert, Stephanie
Hoeppener, Stephanie
Haas, Dorothee
Enzensperger, Christoph
Lehmann, Marc
Babic, Petra
Benecke, Kay Jovana
Traeger, Anja
Bauer, Michael
Schubert, Ulrich S.
Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I
title Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I
title_full Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I
title_fullStr Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I
title_full_unstemmed Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I
title_short Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I
title_sort formulation of liver-specific plga-dy-635 nanoparticles loaded with the protein kinase c inhibitor bisindolylmaleimide i
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698893/
https://www.ncbi.nlm.nih.gov/pubmed/33218172
http://dx.doi.org/10.3390/pharmaceutics12111110
work_keys_str_mv AT shkodrablerina formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT pressadriant formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT vollrathantje formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT nischangivo formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT schubertstephanie formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT hoeppenerstephanie formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT haasdorothee formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT enzenspergerchristoph formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT lehmannmarc formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT babicpetra formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT beneckekayjovana formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT traegeranja formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT bauermichael formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei
AT schubertulrichs formulationofliverspecificplgady635nanoparticlesloadedwiththeproteinkinasecinhibitorbisindolylmaleimidei